4G
4GB.F Gossamer Bio Inc
- Market cap
- EUR 804K
- P/E
- -
- P/B
- 2.50x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4GB.F undervalued?
Graham numberThe Graham number of Gossamer Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gossamer Bio Inc fundamental analysis
No fundamental analysis for Gossamer Bio Inc yet.
Gossamer Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pul…
Full company profileGossamer Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gossamer Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115M | 48.5M | 52.4M |
| Operating Income | -83.0K | -6.65M | -149M | -186M | -211M | -216M | -219M | -174M | -59.9M | -163M | -142M |
| EBITDA | - | - | -147M | -179M | -226M | -209M | -211M | -162M | -40.0M | -158M | -47.6M |
| Net Income | -83.0K | -6.77M | -147M | -180M | -243M | -234M | -229M | -180M | -56.5M | -170M | -59.5M |
| EPS | - | -0.11 | -2.43 | -2.93 | -3.29 | -3.09 | -194 | -64 | -20 | -58 | -9.74 |
| Balance Sheet | |||||||||||
| Total Assets | 60.0K | 445K | 239M | 427M | 539M | 344M | 272M | 312M | 315M | 172M | 76.9M |
| Total Liabilities | 183K | 7.31M | 359M | 74.1M | 219M | 222M | 260M | 249M | 286M | 295M | 171M |
| Shareholders' Equity | -123K | -6.86M | -120M | 352M | 321M | 121M | 12.1M | 62.8M | 29.5M | -123M | -94.0M |
| Cash & Short-term Investments | 60.0K | 315K | 105M | 135M | 486M | 183M | 112M | 32.1M | 46.1M | 37.7M | 41.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 20.0K | -5.75M | -51.0M | -145M | -176M | -189M | -187M | -159M | -3.47M | -171M | -156M |
| Capital Expenditure | 0.00 | 3.49M | 3.49M | 2.97M | 1.50M | 1.55M | 475K | 0.00 | 0.00 | 79.0K | 0.00 |
| Free Cash Flow | - | -5.75M | -72.3M | -151M | -201M | -191M | -188M | -159M | -3.47M | -171M | -156M |
| Ratios | |||||||||||
| ROE | - | - | - | -51.2% | -75.9% | -192.7% | -1,899.3% | -286.5% | -191.7% | - | - |
| ROA | -138.3% | -1,521.6% | -61.4% | -42.3% | -45.1% | -68.1% | -84.2% | -57.6% | -17.9% | -98.9% | -77.4% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -49.3% | -351.5% | -113.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gossamer Bio Inc dividends
Gossamer Bio Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:80 on Sep 11, 2026.
Who owns Gossamer Bio Inc
- Insiders 1.52%
- Institutions 85.86%
- Public & others 12.63%
- Shares outstanding 6.11M
- Free float 3.83M
Gossamer Bio Inc company profile
- Company name
- Gossamer Bio Inc
- Ticker
- 4GB.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Fiscal year end
- December
- Address
- 3115 Merryfield Row, San Diego, CA, United States, 92121
- Phone
- 858 684 1300
- Website
- gossamerbio.com
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio Inc management
10- Mr. Faheem HasnainCo-Founder, CEO, President & Chairman · born 1958
- Mr. Bryan GiraudoCOO & CFO · born 1975
- Mr. Robert Paul Smith Jr.Chief Commercial Officer · born 1969
- Mr. Christian Waage J.D.Executive VP, General Counsel & Secretary · born 1967
- Ms. Jeanine AnthonySenior Vice President of Marketing
- Ms. Deanna WeberExecutive Vice President of Human Resources
- Dr. Robert F. Roscigno Ph.D.Senior Vice President of Clinical Development of Pulmonary Vascular Disease · born 1966
- Ms. Caryn L. PetersonChief Development Officer · born 1959
- Kelly DawsonSenior Vice President & Program Team Lead
- Mr. Conor O'DonovanSenior Vice President of Regulatory Affairs